YBL-012

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameYBL-012

Drug Alias NameYBL-012

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionT cell immunoglobulin and ITIM domains inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants

TargetsT cell immunoglobulin and ITIM domains

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesY-biologics Inc

China Registration ClassN/A

Develop Information

Active CompaniesY-biologics Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A